COPLAND ROAD CAPITAL NEW (A2P) - Net Assets
Based on the latest financial reports, COPLAND ROAD CAPITAL NEW (A2P) has net assets worth €214.19 Million EUR (≈ $250.42 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€565.77 Million ≈ $661.44 Million USD) and total liabilities (€351.57 Million ≈ $411.03 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See how leveraged is COPLAND ROAD CAPITAL NEW's balance sheet to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €214.19 Million |
| % of Total Assets | 37.86% |
| Annual Growth Rate | 36.51% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 14.66 |
COPLAND ROAD CAPITAL NEW - Net Assets Trend (2022–2025)
This chart illustrates how COPLAND ROAD CAPITAL NEW's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see COPLAND ROAD CAPITAL NEW (A2P) total market value.
Annual Net Assets for COPLAND ROAD CAPITAL NEW (2022–2025)
The table below shows the annual net assets of COPLAND ROAD CAPITAL NEW from 2022 to 2025. Also explore net asset growth rate of COPLAND ROAD CAPITAL NEW to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €223.54 Million ≈ $261.34 Million |
+17.64% |
| 2024-12-31 | €190.02 Million ≈ $222.16 Million |
+41.60% |
| 2023-12-31 | €134.20 Million ≈ $156.90 Million |
+52.77% |
| 2022-12-31 | €87.85 Million ≈ $102.70 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to COPLAND ROAD CAPITAL NEW's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 736.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €151.12 Million | 67.60% |
| Other Components | €72.42 Million | 32.40% |
| Total Equity | €223.54 Million | 100.00% |
COPLAND ROAD CAPITAL NEW Competitors by Market Cap
The table below lists competitors of COPLAND ROAD CAPITAL NEW ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tronox Holdings PLC
NYSE:TROX
|
$667.53 Million |
|
Hunan Fangsheng Pharm Co Ltd
SHG:603998
|
$667.57 Million |
|
Bringspring Science and Tech
SHE:300290
|
$668.40 Million |
|
Legacy Housing Corp
NASDAQ:LEGH
|
$668.50 Million |
|
Yesway, Inc. Class A Common Stock
NASDAQ:YSWY
|
$667.37 Million |
|
NanJing GOVA Technology Co. Ltd. A
SHG:688539
|
$667.36 Million |
|
Turaco Gold Ltd
AU:TCG
|
$667.11 Million |
|
Hosken Consolidated Investments Ltd
JSE:HCI
|
$667.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in COPLAND ROAD CAPITAL NEW's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 190,023,972 to 223,540,181, a change of 33,516,209 (17.6%).
- Net income of 102,927,868 contributed positively to equity growth.
- Dividend payments of 70,365,314 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €102.93 Million | +46.04% |
| Dividends Paid | €70.37 Million | -31.48% |
| Other Changes | €953.65K | +0.43% |
| Total Change | €- | 17.64% |
Book Value vs Market Value Analysis
This analysis compares COPLAND ROAD CAPITAL NEW's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.03x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 7.71x to 3.03x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | €10.30 | €79.45 | x |
| 2023-12-31 | €15.73 | €79.45 | x |
| 2024-12-31 | €22.28 | €79.45 | x |
| 2025-12-31 | €26.21 | €79.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently COPLAND ROAD CAPITAL NEW utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 46.04%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 15.10%
- • Asset Turnover: 1.39x
- • Equity Multiplier: 2.19x
- Recent ROE (46.04%) is above the historical average (35.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 11.73% | 6.17% | 0.71x | 2.69x | €1.52 Million |
| 2023 | 39.08% | 11.74% | 1.49x | 2.23x | €39.03 Million |
| 2024 | 43.45% | 13.23% | 1.66x | 1.97x | €63.56 Million |
| 2025 | 46.04% | 15.10% | 1.39x | 2.19x | €80.57 Million |
Industry Comparison
This section compares COPLAND ROAD CAPITAL NEW's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $37,307,353,473
- Average return on equity (ROE) among peers: -16.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| COPLAND ROAD CAPITAL NEW (A2P) | €214.19 Million | 11.73% | 1.64x | $667.40 Million |
| LEPU MED.T.B. SP.GDR O.N. (07Z0) | $17.76 Billion | 5.42% | 0.47x | $157.40K |
| BIORETEC OY (0TN) | $9.74 Million | -47.38% | 0.18x | $16.10 Million |
| SYSMEX CORP.UNSP.ADR 1/2 (0YX0) | $349.05 Billion | 12.63% | 0.39x | $4.70 Billion |
| INMODE LTD IS -01 (154) | $703.81 Million | 25.76% | 0.12x | $711.77 Million |
| HeraMED Limited (1I4) | $-105.98K | 0.00% | 0.00x | $28.30 Million |
| Medtronic PLC (2M6) | $1.33 Billion | 22.02% | 0.46x | $83.04 Billion |
| Peijia Medical Limited (4WO) | $1.86 Billion | -10.94% | 0.43x | $401.71 Million |
| AVITA Medical Inc (51KB) | $20.86 Million | -118.03% | 0.23x | $172.49 Million |
| BRAINCOOL AB (5YL) | $111.74 Million | -54.84% | 0.19x | $18.88 Million |
| MICROPORT CARDIO.MEDTECH. (72X) | $2.22 Billion | -2.23% | 0.20x | $107.57 Million |
About COPLAND ROAD CAPITAL NEW
Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as research, produces, and sells radiopharmaceutical products used in diagnostics … Read more